Keywords
transforming growth factor beta
dystonic disorders
hyperostosis
How to Cite
Abstract
Camurati-Engelmann syndrome, also known as progressive diaphyseal dysplasia, is a rare, autosomal dominant disease with a prevalence of one per million inhabitants. It generates mutations of the transforming growth factor beta, which participates in bone proliferation. Osteomuscular and neurological manifestations are frequent, with few laboratory expressions. The diagnosis is based on the clinic, radiological findings, and genetic confirmation, treatment is aimed at symptom control and prognosis is uncertain. The objective of this publication is to share with the medical community the third case of Camurati-Engelmann syndrome known in Colombia. This is a 33-year old female patient with a clinical picture of intense dystonia and characteristic signs and symptoms of this syndrome, whose diagnosis was confirmed by molecular testing, finding the presence of the pathogenic variant p.Arg156Cys in the TGF-β1 gene, with de novo presentation. MÉD.UIS.2021;34(1): 119-27.
References
Sparkes RS, Graham CB. Camurati-Engelmann disease: genetics and clinical manifestations with a review of the literature. J Med Genet. 1972;9(1):73–85.
Van Hul W, Boudin E, Vanhoenacker FM, Mortier G. Camurati– Engelmann Disease. Calcif Tissue Int. 2019;104(5):554-60.
Boudin E, Van Hul W. Sclerosing bone dysplasias. Best Pract Res Clin Endocrinol Metab. 2018;32(5):707–23.
Cockayne EA. Case for diagnosis. Proc R Soc Med. 1920;13:132–6.
Camurati M. Di un raro caso de osteite simmetrica ereditaria degli arti inferiori. Chir Organi Mov. 1922;6:662–5.
Engelmann G. Ein fall von ostheopathia hyperostotica (sclerotisans) multiplex infantilis. Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin. 1929;39:1101–6.
Neuhauser EBD, Schwachman H, Wittenborg M, Cohen J. Progressive diaphyseal dysplasia. Radiology. 1948;51(1):11–22.
García MD, Vargas C. Síndrome de Camurati-Engelmann. Seminarios de La Fundación Española de Reumatología. 2011;12(3):91–7.
Restrepo JP, Molina MP. Enfermedad de Camurati-Engelmann: Reporte de un caso y revisión de la literatura. Rev Colomb Reumatol. 2016;23(3):218–22.
De Bonilla Á, García FJ. Enfermedad de Camurati-Engelmann. Reumatol Clin. 2017;13(1):48–49.
Ghadami M, Makita Y, Yoshida K, Nishimura G, Fukushima Y, Wakui K, et al. Genetic mapping of the Camurati-Engelmann disease locus to chromosome 19q13.1-13.3. Am J Hum Genet. 2000;66(1):143–7.
Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet. 1999;8(1):93–7.
Janssens K, Ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-β1 to the bone. Endocr Rev. 2005;26(6):743–74.
Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor- β controls the conversion f osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem. 2002;277(46):44061–7.
Karsdal MA, Andersen TA, Bonewald L, Christiansen C. Matrix metalloproteinases (MMPs) safeguard osteoblasts from apoptosis during transdifferentiation into osteocytes: MT1- MP maintains osteocyte viability. DNA Cell Biol. 2004;23(3):155–65.
Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. 2009;13(5):793–802.
Watanabe Y, Kinoshita A, Yamada T, Ohta T, Kishino T, Matsumoto N, et al. A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway. J Hum Genet. 2002;47(9):478-83.
Vega RA, Muñoz JF, Amador JA, Vargas OL. Enfermedad de Camurati-Engelmann: reporte de caso. Rev Colomb Ortop Traumatol. 2013;27(2):131-6.
Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, et al. Mutations in the gene encoding the latencyassociated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet. 2000;26:273-5.
Fox SW, Lovibond AC. Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol. 2005;243(1-2):19–26.
Meczekalski B, Czyzyk A, Podfigurna-Stopa A, Rydzewski B, Sroczynski J, Lipinska M, et al. Hypothalamic amenorrhea in a Camurati-Engelmann disease-a case report. Gynecol Endocrinol. 2013;29(5):511–4.
Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, et al. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data f 24 families and implications for diagnosis and treatment. J Med Genet. 2006;43(1):1–11.
Brat H, Hamoir X, Matthijs P, Lambin P, Van Campenhoudt M. Camurati–Engelmann disease: a late and sporadic case with metaphyseal involvement. Eur Radiol. 1999; 9:159–62.
Nishimura G, Nishimura H, Tanaka Y, Makita Y, Ikegawa S, Ghadami M, et al. Camurati–Engelmann disease type II: Progressive diaphyseal dysplasia with striations of the bones. Am J Med Genet. 2002;107(1):5–11.
Saraiva J. Progressive diaphyseal dysplasia: a three-generation family with markedly variable expressivity. Am J Med Genet.1998;71(3):348–52.
Shier C, Krasicky G, Ellis B, Kottamasu S. Ribbing’s disease: radiographic-scintigraphic correlation and comparative analysis with Engelmann’s disease. J Nucl Med. 987;28(2):244–8.
Vanhoenacker FM, De Beuckeleer LH, Van Hul W, Balemans W, Tan GJ, Hill SC, et al. Sclerosing bone dysplasias: genetic and radioclinical features. Eur Radiol. 2000;10:1423–33.
Campos-Xavier A, Saraiva JM, Savarirayan R, Verloes A, Feingold J, Faivre L, et al. Phenotypic variability at the TGF-β1 locus in Camurati-Engelmann disease. Hum Genet. 2001;109(6):653–8.
Hughes P, Hassan I, Que L, Mead P, Lee JH, Love DR, el at. Observations on the Natural History of Camurati-Engelmann isease. J Bone Miner Res. 2019;34(5):875-82.
Whyte MP, Tau C, McAlister WH, Zhang X, Novack DV, Preliasco V, et al. Juvenile Paget’s disease with heterozygous duplication within TNFRSF11A encoding RANK. Bone. 2014;68:153–61.
Beals RK, Pearson JM, Mansoor A. Ribbing disease: a case report, a review of the literature, and a description of novel treatment. J Bone Joint Surg Am. 2002;84(11):2050–5.
Bartuseviciene A, Samuilis A, Skucas J. Camurati–Engelmann disease: imaging, clinical features and differential diagnosis. Skeletal Radiol. 2009;38(11):1037–43.
Brueton LA, Winter RM. Craniodiaphyseal dysplasia. J Med Genet. 1990;27(11):701–6.
Arora R, Aggarwal S, Deme S. Ghosal hematodiaphyseal dysplasia-a concise review including an illustrative patient. Skeletal Radiol. 2015;44(3):447–450.
Van Hul W, Bollerslev J, Gram J, Van Hul E, Wuyts W, Benichou O, et al. Localization of a gene for autosomal dominant osteopetrosis (Albers–Schoenberg Disease) to chromosome 1p21. Am J Hum Genet. 1997;61(2):363–9.
Freyschmidt J, Freyschmidt-Paul P. SKIBO diseases: a concept to avoid bloody diagnostic procedures in ambiguous skeletal lesions. Eur Radiol. 2001;11(9):1729–42.
Leri A, Joanny J. Une affection non décrite des os hyperostose “en coulée” sur toute la longeur d’un member ou “melorhéostose”. Bull Mem Soc Med Hosp Paris. 1922;46:1141–145.
Baş F, Darendeliler F, Petorak I, Sadikoğlu B, Bilir A, Bundak R, et al. Deflazacort treatment in progressive diaphyseal dysplasia (Camurati- Engelmann disease). J Paediatr Child Health. 1999;35(4):401–5.
Verbruggen LA, Bossuyt A, Schreuer R, Somers G. Clinical and scintigraphic evaluation of corticosteroid treatment in a case of progressive diaphyseal dysplasia. J Rheumatol. 1985;12(4):809–13.
Lehnert SA, Akhurst RJ. Embryonic expression pattern of TGF beta type-1 RNA suggests both paracrine and autocrine mechanisms of action. Development. 1988;104(2):263–73.
Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13(2):204–210.
Inaoka T, Shuke N, Sato J, Ishiwa Y, Takahashi K, Aburano T, et al. Scintigraphic evaluation of pamidronate and corticosteroid therapy in a pacient with progressive diaphyseal dysplasia (Camurati-Engelmann disease). Clin Nucl Med. 2001;26(8):680-2.
Iba K, Takada J, Kamasaki H, Oda T, Hatakeyama N, Wada T, et al. A significant improvement in lower limb pain after treatment with alendronate in two cases of Camurati- ngelmann disease. J Bone Miner Metab. 2008;26(1):107-9.
Hoff AO, Catala-Lehnen P, Thomas OM, Priemel JM, Rueger JM, Nasonkin I, et al. Increased bone mass in an unexpected phenotype associated with deletion of the calcitonin gen. Clin Invest. 2002;110(12):1849-57.
Wong T, Herschman Y, Patel NV, Patel T, Hanft S. Repeat Intracranial Expansion After Skull Regrowth in Hyperostotic Disease: Technical Note. World Neurosurg. 2017;102:555– 60.
Raffaelli P, Ronzini MF. Camurati-Engelmann’s disease. A case report. Ital J Orthop Traumatol. 1988;14(2):267-271.
Frienlad DR, Wackym PA, Rhee JS, Finn MS. Cochlear implantation for auditory rehabilitation in Camurati-Engelmann disease. Ann Otol Rhinol Laryngol. 2000;109(2):160-2.
Szweras M, Liu D, Partridge EA, Pawling J, Sukhu B, Clokie C, et al. Alpha 2-HS glycoprotein/fetuin, a transforming growth factorbeta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem. 2002;277(22):19991-7.
Qin Y, Tang S, Zhen G, Ding Q, Ding S, Cao X. Bone-targeted delivery of TGF-β type 1 receptor inhibitor rescues uncoupled bone remodeling in Camurati–Engelmann disease. Ann N Y Acad Sci. 2018;1433(1):29-40.
Kim YM, Kang E, Choi JH, Kim GH, Yoo HW, Lee BH. Clinical characteristics and treatment outcomes in Camurati-Engelmann disease. A case series. Medicine (Baltimore). 2018;97(14):e0309.
Owhonda RA, Wells JE, Lloyd EW, Mumm S, Kimonis V. A Case Report of a 44-Year-Old Woman with Camurati-Englemann Disease: A Case Report. JBJS Case Connect. 2020;10(3):e1900400.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2021 Médicas UIS